Interestingly, Smyth et al. have previously shown that at least a subset of these acquired HER2 mutations in HER2-positive BC retain sensitivity to neratinib, despite conferring resistance to HER2-directed monoclonal antibodies and reversible kinase inhibitors(Cocco et al. 2018). The gene discussed is ERBB2; the disease is breast cancer.